Summary of ceftaroline fosamil clinical trial studies and clinical safety.
about
Antibiotics for community-acquired pneumonia in adult outpatientsMethicillin-resistant Staphylococcus aureus therapy: past, present, and futureCeftaroline fosamil: a brief clinical review.[Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era].Ceftaroline desensitization procedure in a pregnant patient with multiple drug allergies.Antimicrobial Susceptibility Profiles of Staphylococcus aureus Isolates Recovered from Humans, Environmental Surfaces, and Companion Animals in Households of Children with Community-Onset Methicillin-Resistant S. aureus InfectionsOritavancin for acute bacterial skin and skin structure infections.Ceftaroline Fosamil Use in 2 Pediatric Patients With Invasive Methicillin-Resistant Staphylococcus aureus Infections.Efficacy and Safety of AFN-1252, the First Staphylococcus-Specific Antibacterial Agent, in the Treatment of Acute Bacterial Skin and Skin Structure Infections, Including Those in Patients with Significant ComorbiditiesPBP 4 Mediates High-Level Resistance to New-Generation Cephalosporins in Staphylococcus aureus.Adverse Drug Reactions Associated with Ceftaroline Use: A 2-Center Retrospective Cohort.Pharmacotherapy for pneumococcal infections: an update.Impact of community-associated methicillin resistant Staphylococcus aureus on HIV-infected patients.Treating paediatric community-acquired pneumonia in the era of antimicrobial resistance.Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections.Current and emerging drugs for acute bacterial skin and skin structure infections: an update.Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections in obese patients.Ceftaroline Fosamil for the Treatment of Staphylococcus aureus Bacteremia Secondary to Acute Bacterial Skin and Skin Structure Infections or Community-Acquired Bacterial Pneumonia.Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP).Community-acquired pneumonia: An overview.Ceftaroline for the treatment of osteomyelitis caused by methicillin-resistant Staphylococcus aureus: a case series.Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. Medical Centers in 2010-2011.Pharmacokinetics of single-dose ceftaroline fosamil in children with cystic fibrosis.Community-onset bacteraemia of unknown origin: clinical characteristics, epidemiology and outcome.In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program.Trimethoprim/sulfamethoxazole versus vancomycin in the treatment of healthcare/ventilator-associated MRSA pneumonia: a case-control study.In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance ProgramEvaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetationsAntimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.Ceftaroline fosamil for treating skin and skin structure infections or community-acquired pneumonia in patients with renal insufficiency.Early versus later response to treatment in patients with community-acquired pneumonia: analysis of the REACH studyCeftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance.Ceftaroline-induced eosinophilic pneumonia.Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience.
P2860
Q24193127-122C2604-6F0B-48C4-949A-61B98BE0F086Q27011165-E0BA8201-5292-48C5-AC65-C1CB3514D90DQ33939080-DEE66695-42E1-4E14-BB60-0984A49D5C29Q35619094-092FF1A0-FC54-41E0-84FF-AFAA011F75D9Q35628320-5ECFB119-F195-4FF7-B817-B1BA8D51C344Q36075860-3ECDA3FD-317B-4466-B66E-F1EC535B1821Q36086423-69C9DDD3-DE1F-4BFA-8EB1-4A2E09891A1DQ36451698-85EB72F3-1E6F-4959-BA18-EE23AC6F09C3Q36644729-6A6B2441-432E-462F-91C6-CEF236D989E4Q37023150-B1CA78C5-C4AD-4B05-B842-E54BD87A72EAQ37080538-6B889ED2-0EAA-45CD-A667-9A0A925DCA19Q38068919-DCE3B386-7492-4187-A7CC-C563694CA6E8Q38104279-CDDEB7B2-355E-445E-A1E1-8D8B60EDF482Q38170557-B676F983-7B67-4A19-8164-3B9817E06268Q38185097-2FBB4740-CB8A-44BD-9B7C-769FB33E7A4EQ38242081-C0DB62C0-678E-46EB-85C5-CDB251CC21CEQ38258105-2B67C76B-E399-4432-9ADD-6F8D58683C14Q38312543-16509CD6-BDDA-4D21-BE66-342A0CB4685AQ38394008-AF7D0567-863C-484E-9A96-6344B4813755Q38557188-125DCFFE-428F-4455-BF1D-51E928B3F8CDQ38683859-43138CFB-1DF7-488E-93B4-891B9C1F6F82Q38987098-393C4F1B-AD8E-4493-840C-D0818EF12106Q39766920-412CDF07-C336-497B-882D-ECAD8271C2E1Q40046123-584A8FFE-75B7-4921-A687-18E7CC99343AQ40204414-42DE643D-3D69-42DE-867D-9131B9E5FEC8Q40390434-B43E7FEF-82B1-4FE9-861C-13A11EAE0D39Q40401599-B5CEAEFD-D2BC-4002-B8BB-329902F27B36Q40976207-3CF19602-592A-45AF-92CF-723929458B5DQ41074267-964A9CD6-9E9D-4546-AA1E-2C37C4ABCB89Q41443468-45E22C79-EDE0-4A66-90A4-3007156728CFQ41622845-5E00D626-8B8E-4834-A89B-748F5F81CEE4Q41894467-A221C282-9A5D-4BF6-85AA-59CE8003F9DFQ42206236-74D0F7DB-D4A4-49DE-A277-1D7EAE80BEEFQ45350065-332A1A18-869B-465C-90A4-47D94FD8A41CQ54292686-99BF8B96-8756-4B54-86E0-2BE3BAED45A3
P2860
Summary of ceftaroline fosamil clinical trial studies and clinical safety.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Summary of ceftaroline fosamil clinical trial studies and clinical safety.
@en
type
label
Summary of ceftaroline fosamil clinical trial studies and clinical safety.
@en
prefLabel
Summary of ceftaroline fosamil clinical trial studies and clinical safety.
@en
P2860
P356
P1476
Summary of ceftaroline fosamil clinical trial studies and clinical safety.
@en
P2093
Gary E Stein
Thomas M File
P2860
P304
P356
10.1093/CID/CIS559
P407
P478
55 Suppl 3
P577
2012-09-01T00:00:00Z